Recombinant antibodies against vascular endothelial growth factor (VEGF)

The invention relates to recombinant antibody-related polypeptide molecules which specifically recognise human vascular endothelial growth factor-A (VEGF-A) and interfere with the in vivo proangiogenic and in vitro stimulatory effects thereof. The aforementioned recombinant polypeptide molecules can...

Full description

Saved in:
Bibliographic Details
Main Authors MORERA DIAZ YANELYS, AYALA AVILA MARTA, CHINEA SANTIAGO GLAY, GAVILONDO COWLEY JORGE VICTOR, LAMDAN ORDAS HUMBERTO, ROJAS DORANTES GERTRUDIS, SANTIAGO VISPO NELSON FRANCISC, GUIROLA CRUZ OSMANY
Format Patent
LanguageChinese
English
Published 04.11.2009
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to recombinant antibody-related polypeptide molecules which specifically recognise human vascular endothelial growth factor-A (VEGF-A) and interfere with the in vivo proangiogenic and in vitro stimulatory effects thereof. The aforementioned recombinant polypeptide molecules can affect the proliferation of in vitro human endothelial cells, subcutaneous angiogenesis in mice, induced by matrigel plugs containing VEGF-A, and the growth of human tumours transplanted to nude mice. Some of these molecules prevent choroid neovascularisation in a non-human primate experimental model. Said molecules can be used for passive immunotherapy of pathological entities having a course that is associated with an increase in vasculature, such as age-related macular degeneration (moist type), cancer and the metastasis thereof, neovascular glaucomas, diabetic and neonatal retinopathy, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, organ transplant rejection, hemangiomas an
Bibliography:Application Number: CN200780043733